里格尔制药 RIGL 深 沪
交易中 05-18 10:36:08 美东时间
28.62
-0.390
-1.34%
华盛通- 最 高29.32
- 今 开29.00
- 成交量 6.85万股
- 最 低 28.30
- 昨 收 29.01
- 总市值 52.95万
- 52周最高 52.24
- 市盈率 静 1.47
- 换手率 0.37%
- 52周最低 18.14
- 委 比 -50.12%
- 总股本 1.85万
- 历史最高 114.40
- 量 比 0.77
- 振 幅 3.52%
- 历史最低 6.40
- 每 手 1
- 风险率 8.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.
05-13 02:38
Rigel to Pay $85M Upfront for FDA-Approved VEPPANU; Potential $320M in Milestones Ahead
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that it has entered into an exclusive, global license agreement
05-12 19:15
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.
05-08 05:53
Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M vs $284.068M Est
Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million vs $284.068 million estimate.
05-06 06:23
Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Rigel Pharmaceuticals (NASDAQ:RIGL) released first-quarter financial results an...
05-06 05:20
Rigel Pharmaceuticals Q1 EPS $0.44 Misses $0.76 Estimate, Sales $58.800M Miss $62.392M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.76 by 42.11 percent. This is a 30.16 percent decrease over earnings of $0.63 per share
05-06 04:03
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
Eli Lilly To Terminate Rigel Collaboration On RIPK1 Inhibitor Ocadusertib Effective June 15, 2026; Does Not Expect Future Milestones Or Royalties Under Agreement After Termination
Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. ("Rigel") received written notice from Eli Lilly and Company ("Lilly") of Lilly's election to terminate that certain
04-22 04:23
